Dr. Shaji Kumar on Novel Frontline Treatment Options in Multiple Myeloma

Video

Shaji Kumar, MD, professor of Medicine, Mayo Clinic discusses going beyond bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma.

In the phase III SWOG SO77 the bortezomib triplet showed improved survival over lenalidomide and dexamethasone alone, demonstrating a median progression-free survival (PFS) with the of 43 months versus 30 months with lenalidomide and dexamethasone alone (HR, 0.712; 96% CI, 0.560-0.906; one-sided P = .0018).

The focus should not be to improve on that combination, says Kumar. One option is to consider other proteasome inhibitor (PI)-based triplet therapies. The phase III ENDURANCE trial is comparing the carfilzomib-lenalidomide-dexamethasone combination to bortezomib-lenalidomide-dexamethasone combination in the frontline setting.

Using monoclonal antibodies like daratumumab and elotuzumab in combination with lenalidomide-dexamethasone is also an option, says Kumar. Panobinostat is also being investigated in frontline multiple myeloma.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD